Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab plus nivolumab versus nivolumab in advanced hepatocellular carcinoma after tyrosine kinase inhibitor progression
jRCT2031200442Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of relatlimab and nivolumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate. Started Feb 2021; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031200442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200442.